SGCB and hydrops fetalis: The analyses of RCTs according to the fixed effect model yielded that the use of sGC modulators in HF patients resulted in no significant benefit in the risk of all-cause mortality (RR = 0.97, 95% CI 0.88–1.08, p = 0.62) (Fig. 3).